This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Has Champions Oncology (CSBR) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (CSBR) Outperforming Other Medical Stocks This Year?
Affimed Down After Clinical Hold on Two Early-Stage Studies
by Zacks Equity Research
Affimed (AFMD) puts two phase I studies evaluating its CD19/CD3-targeting T cell engager, AFM11, on clinical hold due to one death and two life-threatening events.
Champions Oncology (CSBR) Soars: Stock Adds 10.7% in Session
by Zacks Equity Research
Champions Oncology (CSBR) saw a big move last session, as its shares jumped nearly 11% on the day, amid huge volumes.
Champions Oncology, Actuant, Caterpillar and Boeing highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Champions Oncology, Actuant, Caterpillar and Boeing highlighted as Zacks Bull and Bear of the Day
Bull Of The Day: Champions Oncology (CSBR)
by Brian Bolan
When was the last time you found a small biotech that promised 20% revenue growth and profitability? Well this one does!
The Zacks Analyst Blog Highlights: Champions Oncology, General Finance, Tilly's, Armstrong Flooring and Medifast
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Champions Oncology, General Finance, Tilly's, Armstrong Flooring and Medifast
Wall Street Bulls to Flourish in Q4: 5 Solid Growth Picks
by Nalak Das
Despite trade war concerns, a robust U.S. economy and strong earnings results boosted investors' confidence in the stock markets.
The Zacks Analyst Blog Highlights: Champions Oncology, CytoDyn, Infinity Pharmaceuticals, Nektar Therapeutics and Zoetis
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Champions Oncology, CytoDyn, Infinity Pharmaceuticals, Nektar Therapeutics and Zoetis
Best ETFs & Stocks From the Top Sector of Q3
by Sweta Killa
Healthcare was the best-performing sector of the third quarter, jumping 14.1% - its highest quarterly gain since the first quarter of 2013.
Endo Recalls 2 Lots of Robaxin Tablets Due to Labeling Error
by Zacks Equity Research
Endo International (ENDP) recalls two lots of Robaxin 750mg Tablets due to wrong dosing information on the label.
5 Best Biotech Stocks to Buy In October
by Zacks Equity Research
Successful drug trials at several biopharmas and FDA approvals make biotech companies a strong investment choice in October
Looking for a Top Momentum Pick? Why Champions Oncology (CSBR) is a Great Choice
by Zacks Equity Research
Does Champions Oncology (CSBR) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks.com highlights: Champions Oncology, STAAR Surgical, Boingo Wireless, Verso and BioSpecifics Technologies
by Zacks Equity Research
Zacks.com highlights: Champions Oncology, STAAR Surgical, Boingo Wireless, Verso and BioSpecifics Technologies
5 Stocks With Recent Price Strength to Strengthen Portfolio
by Zacks Equity Research
Investors target stocks that have been on a bullish run lately. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
Champions Oncology (CSBR) Q1 Earnings Preview: How Are Events Shaping Up?
by Zacks Equity Research
Champions Oncology (CSBR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks.com highlights: Safeguard Scientifics, Exantas Capital, Champions Oncology, Stars Group and GDS Holdings
by Zacks Equity Research
Zacks.com highlights: Safeguard Scientifics, Exantas Capital, Champions Oncology, Stars Group and GDS Holdings
5 Stocks to Buy as New Analysts Show Interest
by Zacks Equity Research
Increased analyst coverage over the last few weeks might translate into solid price appreciation for these stocks.